ELOCP17
associated omics dataQ-omics provides the consensus-scored ELOCP17 profile across patient tissues and cancer cell-line models. ELOCP17 expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in STAD.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes ELOCP17 survival associations across molecular data types. ELOCP17 RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP17 RNA expression–survival associations across cancer types. High ELOCP17 expression shows unfavorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for ELOCP17 RNA expression.
